Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norman Wolmark

Showing results (51-60 of 232) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factorsGong Tang, Jack Cuzick, Joseph P Costantino, et al.
Breast Cancer Research and Treatment|August 21, 2004
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23Stephanie R Land, Jacek A Kopec, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14Norman Wolmark, Eleftherios P Mamounas, Frederick L Baehner, et al.
Journal of the National Cancer Institute|August 26, 2009
Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trialDavid N Krag, Takamaru Ashikaga, Seth P Harlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trialsIrene L Wapnir, Stewart J Anderson, Eleftherios P Mamounas, et al.
Annals of Surgical Oncology|May 31, 2007
Is sentinel node biopsy necessary in conservatively treated DCIS?Thomas B Julian, Stephanie R Land, Virginie Fourchotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06Jacek A Kopec, Greg Yothers, Patricia A Ganz, et al.
Cancer|May 10, 2012
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01Kelley M Kidwell, Greg Yothers, Patricia A Ganz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2012
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)Reena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Cancer|September 14, 2007
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysisJ Philip Kuebler, Linda Colangelo, Michael J O'Connell, et al.
Pageof 24

Showing results (51-60 of 232) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2011
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factorsGong Tang, Jack Cuzick, Joseph P Costantino, et al.
Breast Cancer Research and Treatment|August 21, 2004
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23Stephanie R Land, Jacek A Kopec, Greg Yothers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14Norman Wolmark, Eleftherios P Mamounas, Frederick L Baehner, et al.
Journal of the National Cancer Institute|August 26, 2009
Surgeon training, protocol compliance, and technical outcomes from breast cancer sentinel lymph node randomized trialDavid N Krag, Takamaru Ashikaga, Seth P Harlow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2006
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trialsIrene L Wapnir, Stewart J Anderson, Eleftherios P Mamounas, et al.
Annals of Surgical Oncology|May 31, 2007
Is sentinel node biopsy necessary in conservatively treated DCIS?Thomas B Julian, Stephanie R Land, Virginie Fourchotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2007
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06Jacek A Kopec, Greg Yothers, Patricia A Ganz, et al.
Cancer|May 10, 2012
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01Kelley M Kidwell, Greg Yothers, Patricia A Ganz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2012
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)Reena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Cancer|September 14, 2007
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysisJ Philip Kuebler, Linda Colangelo, Michael J O'Connell, et al.
Pageof 24